Abstract:Introduction Clozapine (CLZ) is an FDA approved second-generation antipsychotic for refractory schizophrenia, and glucuronidation is an important pathway in its metabolism. The aim of this study was to fully characterize the CLZ glucuronidation pathway and examine whether polymorphisms in active glucuronidating enzymes could contribute to variability in CLZ metabolism.Methods Cell lines overexpressing wild-type or variant uridine diphosphate-glucuronosyltransferase (UGT) enzymes were used to determine which UGTs show activity against CLZ and its major active metabolite N-desmethylclozapine (dmCLZ). Human liver microsomes (HLM) were used to compare hepatic glucuronidation activity against the UGT genotype.Results Several UGTs including 1A1 and 1A4 were active against CLZ; only UGT1A4 showed activity against dmCLZ. UGT1A1 showed a 2.1-fold (P < 0.0001) higher V-max/K-M for formation of the CLZ-N+-glucuronide than UGT1A4; UGT1A4 was the only UGT for which CLZ-5-N-glucuronide kinetics could be determined. The UGT1A4(24Pro/48Val) variant showed a 5.2-, 2.0-, and 3.4-fold (P < 0.0001 for all) higher V-max/K-M for the formation of CLZ-5-N-glucuronide, CLZ-N+-glucuronide, and dmCLZ-5-N-glucuronide, respectively, as compared with that of wild-type UGT1A4(24Pro/48Leu). There was a 37% (P<0.05) decrease in the rate of CLZ-N+-glucuronide formation in HLM with the UGT1A1 (*28/*28)/UGT1A4 (*1/*1) genotype, and a 2.2- and 1.8-fold (P < 0.05 for both) increase in the formation of CLZ-5-N-glucuronide and CLZ-N+-glucuronide in UGT1A1 (*1/*1)/UGT1A4 (*3/*3) HLM compared with UGT1A1 (*1/*1)/UGT1A4 (*1/*1) HLM. The UGT1A1*28 allele was a significant (P = 0.045) predictor of CLZ-N+-glucuronide formation; the UGT1A4*3 allele was a significant (P < 0.0001) predictor of CLZ-5-N-glucuronide and dmCLZ-glucuronide formation.Conclusion These data suggest that the UGT1A1*28 and UGT1A4*3 alleles contribute significantly to the interindividual variability in CLZ and dmCLZ metabolism. Pharmacogenetics and Genomics 22: 561-576 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Interspecies variability and drug interactions of clozapine metabolism by microsomes

Interindividual Variation In Relative Cyp1a2/3a4 Phenotype Influences Susceptibility Of Clozapine Oxidation To Cytochrome P450-Specific Inhibition In Human Hepatic Microsomes

Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2‐ and CYP3A4‐selective Inhibitors

Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder

Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2

In Vitro Metabolism of Zolmitriptan in Rat Cytochromes Induced with Β-Naphthoflavone and the Interaction Between Six Drugs and Zolmitriptan

Clozapine-induced hepatotoxicity in rat hepatocytes by gel entrapment and monolayer culture

The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement

Interspecies Variation of Clopidogrel Hydrolysis in Liver Microsomes from Various Mammals.

Clomipramine N-Demethylation Metabolism in Human Liver Microsomes

Individual differences in the pharmacokinetics of clozapine in healthy Chinese adults

Glucuronidation of the Second-Generation Antipsychotic Clozapine and Its Active Metabolite N-Desmethylclozapine. Potential Importance of the Ugt1a1 A(Ta)(7)Taa and Ugt1a4 L48v Polymorphisms

In Vitro and in Vivo Evaluation of the Inhibition Potential of Risperidone Toward Clozapine Biotransformation

Evidence for Involvement of Polymorphic Cyp2c 19 and 2c9 in the N-Demethylation of Sertraline in Human Liver Microsomes

Differential Effects of Clozapine on Ethanol-Induced Ascorbic Acid Release in Mouse and Rat Striatum

Impact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia

Pharmacovigilance of drug-drug interactions: A pharmacokinetic study on the combined oral administration of lurasidone and clozapine in rats by using LC-MS/MS

Effects of 22 CYP2D6 Genetic Variations Newly Identified in Chinese Population on Olanzapine Metabolism in Vitro.

Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro

In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan